Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Bundamedik TbkISX:BMHS 73 Debt-to-EBITDA is 16.79 as of Jun. 2026, which is 311% above its 10-year median of 4.09. GuruFocus rates ISX:BMHS with a GF Score™ of 73/100 and a GF Value™ of Rp265.77 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks worse than 85.98% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Bundamedik Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:BMHS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.23 Med: 4.09 Max: 7.83
Current: 7.83
During the past 8 years, the highest Debt-to-EBITDA Ratio of PT Bundamedik Tbk was 7.83. The lowest was 1.23. And the median was 4.09.
ISX:BMHS's Debt-to-EBITDA is ranked worse than 85.98% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs ISX:BMHS: 7.83
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Bundamedik Tbk Debt-to-EBITDA Related Terms
PT Bundamedik Tbk Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, EHC: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
PT Bundamedik Tbk (ISX:BMHS) has a Debt-to-EBITDA of 16.79 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Bundamedik Tbk. This is 311% above median its historical median of 4.09. Over the past decade, PT Bundamedik Tbk's Debt-to-EBITDA has ranged from 1.23 to 7.83. According to the industry distribution chart, PT Bundamedik Tbk ranks #411 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 86%.
Is PT Bundamedik Tbk's Debt-to-EBITDA too high?
PT Bundamedik Tbk's current Debt-to-EBITDA of 16.79 is 311% above median its 10-year median of 4.09. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 7.83. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. PT Bundamedik Tbk's value of 16.79 is 664.9% above this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #411 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Bundamedik Tbk has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #411 out of 478 companies for Debt-to-EBITDA. This places PT Bundamedik Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. PT Bundamedik Tbk's value of 16.79 is 664.9% above this benchmark. Historically, PT Bundamedik Tbk's own Debt-to-EBITDA has ranged from 1.23 to 7.83 over the past decade. While the company's 10-year median is 4.09 vs. the industry median of 2.20, PT Bundamedik Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current Debt-to-EBITDA of 16.79 is 664.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Bundamedik Tbk. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current Debt-to-EBITDA is 16.79, which is 311% above median its own 10-year median of 4.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp265.77, compared to a current price of Rp193.00 — trading 27.4% below its estimated fair value. The current Debt-to-EBITDA is 16.79, which is 311% above median its 10-year median of 4.09 and 664.9% above the Healthcare Providers & Services industry median of 2.20. PT Bundamedik Tbk's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Debt-to-EBITDA is 16.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp193.00 is trading 27.4% below its estimated GF Value™ of Rp265.77.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
Debt-to-EBITDA: 16.79 (311% above median its 10-year median of 4.09)
GF Value™: Rp265.77 vs. price of Rp193.00 (27.4% below fair value)
Industry Position: 664.9% above the Healthcare Providers & Services median (#411 of 478)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
73GF Score
Get the complete analysis for ISX:BMHS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
